A novel endogenous erythropoietin mediated pathway prevents axonal degeneration
about
Food-Derived Natural Compounds for Pain Relief in Neuropathic PainIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesErythropoietin enhances nerve repair in anti-ganglioside antibody-mediated models of immune neuropathyErythropoietin promotes Schwann cell migration and assembly of the provisional extracellular matrix by recruiting beta1 integrin to the cell surfaceErythropoietin overrides the triggering effect of DNA platination products in a mouse model of cisplatin-induced neuropathy.Prevention of diabetic neuropathy by regulatable expression of HSV-mediated erythropoietin.Mitochondrial dysfunction in distal axons contributes to human immunodeficiency virus sensory neuropathyNitric oxide prevents axonal degeneration by inducing HIF-1-dependent expression of erythropoietin.Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia.Systemic adeno-associated virus-mediated gene therapy preserves retinal ganglion cells and visual function in DBA/2J glaucomatous miceThe effects of potential neuroprotective agents on rat facial function recovery following facial nerve injury.Human Schwann cells retain essential phenotype characteristics after immortalizationErythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID miceNeurorestorative treatment of stroke: cell and pharmacological approaches.Schwann cells: activated peripheral glia and their role in neuropathic pain.The therapeutic potential of gene transfer for the treatment of peripheral neuropathies.Erythropoietin and polyneuropathy in older personsAdvancement of therapies for neuroprotection in multiple sclerosis.Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system.Dorsal Root Ganglia Sensory Neuronal Cultures: a tool for drug discovery for peripheral neuropathies.Schwann cells as a therapeutic target for peripheral neuropathies.Axonal degeneration as a therapeutic target in the CNS.Concepts for regulation of axon integrity by enwrapping glia.Molecules involved in the crosstalk between immune- and peripheral nerve Schwann cells.CXCR4/CXCR7 molecular involvement in neuronal and neural progenitor migration: focus in CNS repair.Sciatic nerve regeneration by transplantation of Schwann cells via erythropoietin controlled-releasing polylactic acid/multiwalled carbon nanotubes/gelatin nanofibrils neural guidance conduit.Cerebral preconditioning using cortical application of hypertonic salt solutions: upregulation of mRNAs encoding inhibitors of inflammation.Compartmentalized microfluidic culture platform to study mechanism of paclitaxel-induced axonal degeneration.Recombinant Human Erythropoietin: Novel Strategies for Neuroprotective/Neuro-regenerative Treatment of Multiple SclerosisErythropoietin attenuates advanced glycation endproducts-induced toxicity of Schwann cells in vitro.Erythropoietin Enhanced Recovery After Traumatic Nerve Injury: Myelination and Localized EffectsErythropoietin enhanced recovery after peripheral nerve injuryc-Jun activation in Schwann cells protects against loss of sensory axons in inherited neuropathy.Erythropoietin: a multimodal neuroprotective agent.Diabetic Schwann cells suffer from nerve growth factor and neurotrophin-3 underproduction and poor associability with axons.Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis.Platelet-derived growth factors-BB and fibroblast growth factors-base induced proliferation of Schwann cells in a 3D environment.Erythropoietin attenuates oxidative stress and apoptosis in Schwann cells isolated from streptozotocin-induced diabetic rats.Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability.Erythropoietin accelerates functional recovery after moderate sciatic nerve crush injury.
P2860
Q28068743-AB51027C-7F46-47C0-B6C5-7D214909D0E8Q28388335-BD0B9209-27E1-4077-B528-F65098C63F55Q28477706-9E3942EE-C0D7-47EE-818B-6485255C61CFQ28580949-DC8D9699-6F14-45AD-B4B4-6638AB35390EQ33482074-461D1E81-2ADF-4B2E-A1E3-9B56977568E3Q34556841-BBEEC4E6-3083-492A-8358-47C0F788638EQ34636367-43F8CCFB-2D4D-48D0-8664-8ACCBF091477Q34720972-AC8829A3-3349-4588-B23B-85287B86DFE7Q35448895-D8A90AF5-DD91-432C-8F65-ADE4AB9E3055Q35496394-2F0F1F46-486E-4BF5-A71A-07603BECD585Q35556725-2CC0BAF3-A71B-43D1-B02E-D54263F6A54CQ35737471-55688024-4553-4C99-BC8D-9DCD8AADFCD9Q36445059-475EC5CA-0D4F-4154-B06B-1DD8C338E4B6Q36608810-464E2C47-5B02-49AC-A98F-E2D61469B089Q36744958-1C85F842-4526-4C45-B797-6C458F7CCBF5Q36762639-A72FF1C0-7D41-4EC5-82B6-D961B50338C9Q37174891-94EDB238-C95D-420A-94E9-36065E0270C5Q37256701-59ED503E-8920-4F4C-BFF2-A00D62DBF1EEQ37358669-14D98C02-B7A9-41E6-BCA2-FEE1E9389655Q37775522-C6D15F67-0806-4738-9EAE-12E64537A05BQ37793315-6CDEA43B-5F57-475F-8D04-2D7387E94C47Q37990880-08AFC4FE-9AE1-4C81-9078-4B801B9255CCQ38175969-96204765-DEAF-4024-9A46-D41363D080DAQ38205157-DA90DD9E-D6EA-4FB4-B761-E254372A0C3FQ38218915-A747BFD8-C3FC-4D61-8073-5B1004824B12Q38694547-52F0F7F0-120B-4A3F-92FF-2A9B99A8DE82Q39669203-7D58D67F-9371-42B6-A639-9D7D21E192D8Q40947311-E2075411-266B-4156-8BA8-C41E60325475Q41173431-408A71AC-F035-4B8A-8991-34793C11073AQ41587516-58F63DAB-A39C-431F-850D-B1135A45A323Q41648362-9004E767-11BA-4313-B7DF-245C2C7F3422Q41667357-29EC7307-028A-464B-A5E0-BEA5EE97815DQ41913075-4D2B58C6-F84F-475A-93B7-BE0EC1A62210Q42922791-3ACA6170-A24F-4DC3-921E-FBD84F9D4F0BQ43778631-EED73587-077B-4E14-8FBC-0B7C225CC8EAQ45076147-F0965A18-17D8-42CA-BF60-EDE9530735BDQ45756439-8591B7A0-07D8-4116-BE60-BA00D90D337DQ46913735-65268EF6-B1BA-4336-902D-32FF2F46AD41Q50592658-784FBA82-23B4-4348-A14B-50C333D432F2Q51149238-26DF1A14-87BA-4DA0-AF10-1DC6E98F490B
P2860
A novel endogenous erythropoietin mediated pathway prevents axonal degeneration
description
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2004
@ast
im Dezember 2004 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2004/12/01)
@sk
vědecký článek publikovaný v roce 2004
@cs
wetenschappelijk artikel (gepubliceerd op 2004/12/01)
@nl
наукова стаття, опублікована в грудні 2004
@uk
مقالة علمية (نشرت في ديسمبر 2004)
@ar
name
A novel endogenous erythropoietin mediated pathway prevents axonal degeneration
@ast
A novel endogenous erythropoietin mediated pathway prevents axonal degeneration
@en
A novel endogenous erythropoietin mediated pathway prevents axonal degeneration
@nl
type
label
A novel endogenous erythropoietin mediated pathway prevents axonal degeneration
@ast
A novel endogenous erythropoietin mediated pathway prevents axonal degeneration
@en
A novel endogenous erythropoietin mediated pathway prevents axonal degeneration
@nl
prefLabel
A novel endogenous erythropoietin mediated pathway prevents axonal degeneration
@ast
A novel endogenous erythropoietin mediated pathway prevents axonal degeneration
@en
A novel endogenous erythropoietin mediated pathway prevents axonal degeneration
@nl
P2093
P356
P1433
P1476
A novel endogenous erythropoietin mediated pathway prevents axonal degeneration
@en
P2093
Ahmet Hoke
Angela Fischer
Christelene Jack
Chunhua Zhou
Gerhard J. Leitz
Hong Liang
Michelle Polley
Nicole Reed
Sanjay C. Keswani
Ulas Buldanlioglu
P304
P356
10.1002/ANA.20285
P577
2004-12-01T00:00:00Z